Cytochrome P450 17 (CYP17) is involved in endometrial cancinogenesis through apoptosis and invasion pathways

Molecular Carcinogenesis

Volumn 50, Issue 1, 2011, Pages 16-23

  Chen, Yi ^a   Saini, Sharanjot ^a   Zaman, Mohd Saif ^a   Hirata, Hiroshi ^a   Shahryari, Varahram ^a   Deng, Guoren ^a   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; CYP17; Endometrial cancer; Invasion

Indexed keywords

CD146 ANTIGEN; CYTOCHROME P450 17; MATRIX METALLOPEPTIDASE 2; MATRIX METALLOPEPTIDASE 9; MATRIX METALLOPROTEINASE; PROTEIN BCL 2; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DEPLETION; DOWN REGULATION; ENDOMETRIAL CARCINOGENESIS; ENDOMETRIUM CANCER; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE; TISSUE ARRAY ANALYSIS; UP-REGULATION;

EID: 78650196753     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20680     Document Type: Article

References (35)

1. Berstein LM, Imyanitov EN, Gamajunova VB, et al. CYP17 genetic polymorphism in endometrial cancer: Are only steroids involved? Cancer Lett 2002;180:47-53.
2. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001;61:3955-3960.
3. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-242.
4. Chen Y, Gammon MD, Teitelbaum SL, et al. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: Results from the Long Island Breast Cancer Study Project. Carcinogenesis 2008;29:766-771.
5. John ME, John MC, Boggaram V, Simpson ER, Waterman MR. Transcriptional regulation of steroid hydroxylase genes by corticotropin. Proc Natl Acad Sci USA 1986;83:4715-4719.
6. Ambrosone CB, Moysich KB, Furberg H, et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003;5:R45-R51.
7. Gsur A, Bernhofer G, Hinteregger S, et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000;87:434-437.
8. Madigan MP, Gao YT, Deng J, et al. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China. Int J Cancer 2003;107:271-275.
9. Olson SH, Orlow I, Bayuga S, et al. Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control 2008;19:955-963.
10. Szyllo K, Smolarz B, Romanowicz-Makowska H, Kulig A. The polymorphisms of the CYP17 and CYP19 genes in endometrial cancer patients. Pol J Pathol 2006;57:35-40.
11. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5:610-620.
12. Cosulich SC, Savory PJ, Clarke PR. Bcl-2 regulates amplification of caspase activation by cytochrome c. Curr Biol 1999;9:147-150.
13. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656.
14. Schmitt CA. Senescence, apoptosis and therapy-Cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286-295.
15. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
16. Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. J Urol 2005;173:1778-1783.
17. Wu GJ, Peng Q, Fu P, et al. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 2004;327:201-213.
18. Aldovini D, Demichelis F, Doglioni C, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 2006;119:1920-1926.
19. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326.
20. Hao XP, Ilyas M, Talbot IC. Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence. Pathobiology 1997;65:140-145.
21. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29-40.
22. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100:3935-3941.
23. Reeve JG, Xiong J, Morgan J, Bleehen NM. Expression of apoptosis-regulatory genes in lung tumour cell lines: Relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 1996;73:1193-1200.
24. Porichi O, Nikolaidou ME, Apostolaki A, et al. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res 2009;29:3977-3982.
25. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-339.
26. Sasgary S, Wieser M, Cerni C. Targeted inhibition of telomerase in human cancer: Will it be a double-edged sword? Onkologie 2001;24:22-26.
27. Binz N, Shalaby T, Rivera P, Shin-ya K, Grotzer MA. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer 2005;41:2873-2881.
28. Hao ZM, Luo JY, Cheng J, et al. Intensive inhibition of hTERT expression by a ribozyme induces rapid apoptosis of cancer cells through a telomere length-independent pathway. Cancer Biol Ther 2005;4:1098-1103.
29. Wu P, Meng L, Wang H, et al. Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor. Biochem Biophys Res Commun 2005;335:36-44.
30. Karahan N, Guney M, Baspinar S, Oral B, Kapucuoglu N, Mungan T. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 2007;28:184-188.
31. Aglund K, Rauvala M, Puistola U, et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004;94:699-704.
32. Tunuguntla R, Ripley D, Sang QX, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003;89:453-459.
33. Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 1999;189:4-11.
34. Kristiansen G, Yu Y, Schluns K, Sers C, Dietel M, Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol 2003;25:77-81.
35. Saini S, Hirata H, Majid S, Dahiya R. Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Res 2009;69:7038-7045.